PHEBRA has announced the launch of its own brand of Phosphate 500mg effervescent tablets to replace the discontinued Phosphate Sandoz (Novartis generics) product.
Phosphate Phebra is listed on the PBS for the treatment of certain diseases that cause hypophosphataemia.
Phebra CEO Dr Mal Eutick said the company had been working in collaboration with Novartis "to ensure that Australian patients continue to have access to this clinically important medicine".
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Dec 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Dec 18
